Omega Diagnostics : VISITECT® CD4 CE-Mark

Regulatory Story

Go to market news section

Omega Diagnostics Group PLC - ODX Released 07:00 29-Nov-2017

RNS Number : 7714X

Omega Diagnostics Group PLC 29 November 2017

VISITECT® CD4 CE-Mark

Omega Diagnostics Group PLC ("Omega" or the "Company") VISITECT® CD4 CE-Mark

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has CE-Marked its VISITECT® CD4 test for helping to manage people living with HIV, following successful performance evaluations in India and the UK.

The successful completion of the CE-Mark process means these tests, which indicate whether a person's CD4 count is higher or lower than 350 cells/mm³, are available for general sale through business to business channels in countries not requiring individual product registration. The technical file forms the basis of the additional regulatory approval the Company will seek through the World Health Organisation Prequalification programme which assesses in vitro diagnostics tests for priority diseases and their suitability for use in resource-limited settings. A successful completion of this process will enable Omega to become eligible for public sector procurement. The Company anticipates that this process is likely to be completed during the second half of the next financial year.

In addition, the Company is looking to expand its VISITECT® product porfolio and is working on an additional version of the VISITECT® CD4 test which utilises a 200 cells/ mm³ cut-off. Recent global health guidelines confirm an opportunity also exists for a test that can indicate advanced HIV disease (a CD4 cell count which is lower than 200 cells/mm³) and the Company is working to ensure it has a product porfolio encompassing both existing and new opportunities.

Andrew Shepherd, Chief Executive Officer of Omega, commented: "We are pleased to have achieved this major milestone and whilst the early opportunities are likely to lead to modest sales during the next twelve months, we anticipate generating significant demand once we

have completed all the regulatory hurdles. We look forward to providing the global health community with unique point-of-care tests which address a significant unmet need."

Contacts: Omega Diagnostics Group PLC Tel: [phone]

Andrew Shepherd, Chief Executive

Kieron Harbinson, Group Finance Director Jag Grewal, Group Sales and Marketing Director

www.omegadiagnostics.com

finnCap Ltd	Tel: [phone]
Geoff Nash/James Thompson	(Corporate
Finance)
Mia Gardner (Corporate Broking)

Walbrook PR Limited Tel: [phone] or

[e-mail]

Paul McManus Mob: [phone]

Lianne Cawthorne Mob: [phone]

This information is provided by RNS

The company news service from the London Stock Exchange

END

RESUWVNRBUAAUAA

CLOSE

Sponsored Business Content

3 Shares With Potential To Beat Brexit Uncertainty

Hargreaves Lansdown

Get the outlook for the coming months from

global fund managers

Russell Investments

Aberdeen Frontier Markets: Diversified access

to up-and-coming markets

Aberdeen Investment Trusts

Beyond the election: why we must keep the

long-term view in sight

BlackRock

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

©2014 London Stock Exchange plc. All rights reserved

VISITECT® CD4 CE-Mark - RNS